Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: A pilot study

Clinical and Experimental Immunology

Volumn 184, Issue 3, 2016, Pages 284-292

  Alunno, A ^a   Carubbi, F ^b   Bistoni, O ^a   Caterbi, S ^a   Bartoloni, E ^a   Di Benedetto, P ^b   Cipriani, P ^b   Giacomelli, R ^b   Gerli, R ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Rituximab; Salivary glands; Sj gren's syndrome; Th17 cells

Indexed keywords

CD20 ANTIGEN; INTERLEUKIN 17; RITUXIMAB; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; DEXAMETHASONE; DEXAMETHASONE 21-PHOSPHATE; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SJOEGREN SYNDROME; T LYMPHOCYTE; TH17 CELL; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PRIMARY CELL CULTURE; SALIVARY GLAND; SJOGREN'S SYNDROME;

ADRENAL CORTEX HORMONES; ADULT; ANTIGENS, CD20; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; DEXAMETHASONE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-17; MIDDLE AGED; PILOT PROJECTS; PRIMARY CELL CULTURE; RITUXIMAB; SALIVARY GLANDS; SJOGREN'S SYNDROME; TH17 CELLS;

EID: 84959526492     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12771     Document Type: Article

References (33)

1. Ambrosi A, Wahren-Herlenius M. Update on the immunobiology of Sjogren's syndrome. Curr Opin Rheumatol 2015; 27:468-75.
2. Brito-Zerón P, Ramos-Casals M. Advances in the understanding and treatment of systemic complications in Sjögren syndrome. Curr Opin Rheumatol 2014; 26:520-7.
3. Cornec D, Jamin C, Pers JO. Sjögren's syndrome: where do we stand, and where shall we go? J Autoimmun 2014; 51:109-14.
4. Routsias JG, Goules JD, Charalampakis G, Tzima S, Papageorgiou A, Voulgarelis M. Malignant lymphoma in primary Sjögren's syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum 2013; 43:178-86.
5. Lin X, Rui K, Deng J et al. Th17 cells play a critical role in the development of experimental Sjogren's syndrome. Ann Rheum Dis 2015; 74:1302-10.
6. Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome. Arthritis Rheum 2008; 58:734-74.
7. Nguyen CG, Yin H, Lee BH, Carcamo WC, Chiorini JA, Peck AB. Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther 2010; 12:R220.
8. Alunno A, Bistoni O, Bartoloni E et al. IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. Ann Rheum Dis 2013; 72:286-92.
9. Lin X, Tian J, Rui K et al. The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans. Ann Rheum Dis 2014; 73:e43.
10. Alunno A, Carubbi F, Caterbi S et al. The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans. Ann Rheum Dis 2014; 73:e42.
11. Alunno A, Carubbi F, Bistoni O et al. CD4-CD8- T-cells in primary Sjögren's syndrome: association with the extent of glandular involvement. J Autoimmun 2014; 51:38-43.
12. Alunno A, Montanucci P, Bistoni O et al. In vitro immunomodulatory effects of microencapsulated umbilical cord Wharton jelly-derived mesenchymal stem cells in primary Sjögren's syndrome. Rheumatology (Oxf) 2015; 54:163-8.
13. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012; 8:399-411.
14. Brito-Zerón P, Sisó-Almirall A, Bové A, Kostov BA, Ramos-Casals M. Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. Expert Opin Pharmacother 2013; 14:279-89.
15. Carubbi F, Alunno A, Cipriani P et al. Rituximab in pSS: a ten-year journey. Lupus 2014; 23:1337-49.
16. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-37.
17. Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 2013; 65:2783-90.
18. Eggleton P, Bremer E, Tarr JM et al. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Res Ther 2011; 13:R208.
19. van de Veerdonk FL, Lauwerys B, Marijnissen RJ et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011; 63:1507-16.
20. Abdulahad WH, Meijer JM, Kroese FG. B-cell reconstitution and T-helper-cell balance after rituximab treatment of active primary Sjogren's syndrome. Arthritis Rheum 2011; 63:1116-23.
21. Ciccia F, Guggino G, Rizzo A et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjogren's syndrome. Rheumatology (Oxf) 2014; 53:1313-20.
22. Ciccia F, Giardina A, Rizzo A et al. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. Ann Rheum Dis 2013; 72:782-3.
23. Carubbi F, Cipriani P, Marrelli A et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013; 15:R172.
24. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-8.
25. Seror R, Ravaud P, Bowman SJ et al. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010; 69:1103-9.
26. Conti F, Perricone C, Ceccarelli F, Valesini G. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev 2010; 9:716-20.
27. Datta SK. Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheumatol 2009; 5:80-2.
28. Wilk E, Witte T, Marquardt N et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum 2009; 60:3563-71.
29. Pers JO, Devauchelle V, Daridon C et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007; 56:1464-77.
30. Alunno A, Bistoni O, Caterbi S, Bartoloni E, Cafaro G, Gerli R. Serum interleukin-17 in primary Sjögren's syndrome: association with disease duration and parotid gland swelling. Clin Exp Rheumatol 2015; 33:129.
31. Hsu HC, Yang P, Wang J et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008; 9:166-75.
32. Alunno A, Carubbi F, Bistoni O et al. T regulatory and T helper 17 cells in primary Sjögren's syndrome: facts and perspectives. Mediators Inflamm 2015; 2015:243723.
33. Alunno A, Carubbi F, Bartoloni E et al. Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: a new era for therapeutic targeting? Autoimmun Rev 2014; 13:1167-73.